NEW ORLEANS, March 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the results of the randomized PARTNER 3 Trial demonstrated superiority for the SAPIEN 3 transcatheter aortic valve over outcomes with surgery.
The trial, which compared treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery, achieved superiority of its primary endpoint at one year. The results of the trial will be presented on Sunday as part of the late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans, and have been published online in the New England Journal of Medicine.
The PARTNER 3 Trial was an independently evaluated, randomized clinical trial comparing outcomes between transcatheter aortic valve replacement (TAVR) and open-heart surgery in this patient group. TAVR with the SAPIEN 3 valve achieved superiority, with a 46 percent reduction in the event rate for the primary endpoint of the trial, which was a composite of all-cause mortality, all stroke and rehospitalization at one year.
"From the first TAVR case more than 17 years ago, to the extensive series of rigorous clinical trials to date, the PARTNER studies have shown increasingly robust outcomes with TAVR and have supported the treatment of hundreds of thousands of patients globally. This demonstrates that TAVR is a proven therapy for severe aortic stenosis, a deadly and debilitating disease that has a worse outlook than many cancers," said Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Medical Center and professor of medicine at the Columbia University College of Physicians and Surgeons. Leon is the national co-principal investigator of the PARTNER 3 Trial. "In the PARTNER 3 Trial, TAVR with the SAPIEN 3 valve showed a remarkably low death and disabling stroke rate of 1.0 percent at one year versus 2.9 percent for surgery. Based upon these clinical trial findings at one year, TAVR should be considered the preferred therapy in low surgical risk aortic stenosis patients."
The PARTNER 3 Trial randomized 1,000 patients at 71 centers between March 2016 and October 2017. Patients were assigned to undergo either TAVR with the SAPIEN 3 valve or surgery with any commercially available surgical valve. All patients were followed for at least one year, and 10-year clinical and echocardiographic follow-up is planned for all patients.
"These data demonstrate that TAVR with the SAPIEN 3 valve gives low surgical risk patients with severe AS a treatment with better outcomes, less time in the hospital and the ability to resume their everyday lives more quickly," said Larry Wood, corporate vice president, transcatheter aortic valve replacement. "It is also highly encouraging to see that 96 percent of TAVR patients were discharged to home as opposed to remaining in a hospital or specialized care setting."
More than 600,000 patients around the world have benefitted from TAVR. The SAPIEN 3 valve is approved in the United States for the treatment of intermediate and higher risk patients with severe, symptomatic AS; it is not yet approved for the treatment of low-risk patients. Edwards continues to anticipate U.S. Food and Drug Administration approval of a low-risk indication for the SAPIEN 3 valve late this year.
Endpoint 30 Days p-value‡ 1 Year p-value‡
TAVR (N=496) SAVR(N=454) TAVR (N=496) SAVR(N=454)
All-cause death, 4.2% 9.3% 0.002 8.5% 15.1% 0.001
all stroke, and
All-cause death 0.4% 1.1% 0.21 1.0% 2.5% 0.09
All stroke 0.6% 2.4% 0.02 1.2% 3.1% 0.04
Death or disabling 0.4% 1.3% 0.12 1.0% 2.9% 0.03
Rehospitalization† 3.4% 6.5% 0.04 7.3% 11.0% <0.05
† Rehospitalization (valve-related or procedure-related and including heart failure)
‡ p-values is based on a log-rank test
All event rates are Kaplan-Meier estimates
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.
CONTACT: Media, Heather Bukant, 949-250-5070, or Investors, David K. Erickson, 949-250-6826, both of Edwards Lifesciences Corporation